Sayre Therapeutics raises $8 mn from Accel Partners & Aarin Capital

Sayre Therapeutics, a super-specialty pharmaceutical company with a portfolio of Oncology, Interventional Oncology and Immunology drugs, drug delivery devices and next-generation diagnostics, has raised $8 mn USD across two rounds of funding from Accel Partners and Aarin Capital. The company has also raised $1Mn USD in venture-debt from InnoVen Capital.
The Bengaluru-based Sayre Therapeutics plans to use the funds for team expansion in India, geographical footprint in other South Asian countries, and invest in clinical trials for their novel in-licensed assets.
According to Shukrit Chimote, Chief Executive Officer, Sayre, the follow-on investment from the venture capitalists were based on the early traction seen in building a product pipeline through partnerships with global and domestic partners, a sales footprint in India and a strong team to capitalise on a USD 650MM market for Oncology and Immunology segments in the region”.

“We seek to fill the gaps in early cancer diagnosis and treatment by licensing in novel drugs, devices and diagnostics to the country at an affordable cost, and a significant discount to the global prices. We will continue to expand the scope of medical care by bringing in these advanced medical technologies and drugs, and thereby provide more options to the physicians and patients in the subcontinent,” said Vandana Subramanian, Chief Business Officer, Sayre. 

 “Our medical science liaisons and key account managers continue to partner doctors and educate patients on new solutions in the fast-evolving field of cancer,” said Praveen Bose, SVP & Head, Sales & Marketing, Sayre.

Sayre is South Asia’s only integrated platform for disease management backed by a unique distribution and commercialization model for novel and / or differentiated drugs, molecular diagnostics and drug-delivery devices in the super-specialty areas of Oncology, Interventional Oncology and Immunology. It was set up in 2015 backed by leading global venture capital firms – Accel Partners & Aarin Capital. The team has years of global executive experience in leading pharmaceuticals, medical diagnostics & devices companies. The company is creating a portfolio of differentiated global assets in emerging markets, including India, Sri Lanka, Bangladesh and Nepal, which are witnessing high growth for pharmaceutical products. Sayre has a geographically focused strategy, strong financial backing and a solid understanding of the clinician networks and the regulatory landscape in the region.



Popular posts from this blog

EMA Recommends Extension of Indications for Ramucirumab

Dr. Hootie Warren takes helm of Fred Hutch Global Oncology

Is Indian pharma ready to tap the European market?